Ŀ¼ U{oM*[
ͬ¼ÃÒ½¿Æ´óѧ1999ÄêÄÚ¿ÆÑ§ÊÔÌâ W5`p Qdk
ͬ¼ÃÒ½¿Æ´óѧ2000ÄêÄÚ¿ÆÑ§ÊÔÌâ A~a 3bCX+"
ÄϾ©Ò½¿Æ´ó99ÄêÉñ¾²¡Ñ§ lD[@D9
ºÓ±±Ò½¿Æ´ó2001ÄêÉñ¾²¡Ñ§ÊÔÌâ Q`AlK"G,
2005ÄêÖÐɽҽ´ó²¡ÉúÊÔÌâ sa o &
ÄÏ·½Ò½¿Æ´óѧ2005ÃâÒßÌâ b,~pwbHf
2005ÄêкͲ©Ê¿ÃâÒßÊÔÌ⣨רҵ»ù´¡£© Bx|W#:3e
2005Äêͬ¼Ã²©Ê¿ÈëѧÕï¶ÏÌâ ~=OJCKv5(
2005É϶þÒ½²©Ê¿·Ö×ÓÉúÎïѧ£¨×¨Òµ»ù´¡£© GyQF
R ?
2005ÄêÉ϶þÒ½²©Ê¿Éú»¯¿¼Ìâ O5p$
A@
ÄÏ·½Ò½¿Æ´óѧ2005ϸ°ûÉúβ©ÊÔÌâ Sj(>G;
2005Ä긴µ©´óѧ·ÅÁÆ¿¼²©ÊÔÌâ _^GBfM.
ͬ¼ÃÒ½¿ÆÔºÀúÄêÉñ¾½âÆÊѧÊÔÌâ )Wq1af
2004ÄêÊ×Ò½Éñ¾½âÆÊÌâ W1"N
Kg~4
µÚËľüÒ½´óѧÀúÄêÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ HLV8_~gQPf
V
>
)/z|[
¾ßÌå¼ûÏÂ: B;=Z^$%T
3R%JmLM+R9
ͬ¼ÃÒ½¿Æ´óѧ1999ÄêÄÚ¿ÆÑ§ÊÔÌâ uVU)LOx
Ò»¡¢ Ãû´Ê½âÊÍ£º1¡¢¾üÍžú²¡Àú¡¢¸ßѪѹÄÔ²¡3¡¢Î¸ÃÚËØÁö4¡¢Õù½øÐÔÉöÑ×5¡¢PhȾɫÌå6¡¢Grares²¡ k0V]<#h87
¶þ¡¢Ìî¿Õ£º1¡¢ÂýÐÔºôÎüË¥½ßIÐ͵ÄÑªÆø·ÖÎöÌØµã£¨1£© £¬IIÐ͵ÄÑªÆø·ÖÎöÌØµã£¨2£© ¡£ 2¡¢ÐÄÔà´«µ¼ÒõÖͰüÀ¨£¨1£© £¨2£© £¨3£© £¨4£© ¡£ 3¡¢Ä¿Ç°ÒÖÖÆÎ¸Ëá·ÖÃÚ×îÇ¿µÄÒ»ÀàÒ©ÊÇ£¨1£© 4¡¢½áºËÐÔ¸¹Ä¤Ñ××î³£¼ûµÄ²¢·¢Ö¢ÊÇ£¨1£© 5¡¢¼±ÐÔÉö¹¦ÄÜË¥½ßÁÙ´²Ò»°ã·ÖΪ£¨1£© £¨2£© £¨3£© ÈýÆÚ¡£ 6¡¢ÓлúÁ×ũҩÖж¾µÄ»úÀíÖ÷ÒªÊÇÒÖÖÆÁË£¨1£© £»Ò»Ñõ»¯Ì¼Öж¾Ê±£¬»úÌå¶ÔȱÑõ×îÃô¸ÐµÄÆ÷¹ÙÊÇ£¨2£© £¨3£© ¡£ 7¡¢¸ù¾Ý²¡ÒòºÍ·¢²¡»úÖÆ£¬½«Æ¶Ñª·ÖΪ£¨1£© £¨2£© £¨3£© ÈýÀà¡£ 8¡¢¼±ÐÔ°×Ѫ²¡µÄMIC·ÖÐÍÊÇÖ¸£¨1£© £¨2£© £¨3£© µÄ·ÖÐÍ¡£9¡¢¿Ú·þ½µÌÇÒ©Îï·ÖΪ£¨1£© ºÍ£¨2£© Á½Àà¡£ 10¡¢Ð¡¼ÁÁ¿µØÈûÃ×ËÉÒÖÖÆÊÔÑéÖ÷ÒªÓÃÓÚ£¨1£© Ó루2£© µÄ¼ø±ðÕï¶Ï£»´ó¼ÁÁ¿µØÈûÃ×ËÉÒÖÖÆÊÔÑéÖ÷ÒªÓÃÓÚ£¨3£© ºÍ£¨4£© µÄ¼ø±ð¡£ BI)C\D3[
Èý¡¢ ¼ò´ðÌ⣺1¡¢¼òÊöÂýÐÔÖ§Æø¹ÜÑ×µÄÕï¶Ï±ê×¼¡£2¡¢ºÎΪǰ¸ººÉ¡¢ºó¸ººÉ£¿3¡¢Ô·¢ÐԸΰ©×ÛºÏÕ÷ÓÐÄÄЩ±íÏÖ£¿ F6yFKNK!n
Pa d)|
ͬ¼ÃÒ½¿Æ´óѧ2000ÄêÄÚ¿ÆÑ§ÊÔÌâ r4iNX+h?V
Ò»¡¢ Ãû´Ê½âÊÍ£º1¡¢ÕÅÁ¦ÐÔÆøÐØ2¡¢ÐÄÁ¦Ë¥½ß3¡¢Grey-TurnerÕ÷4¡¢IgAÉö²¡5¡¢AureСÌå6¡¢Ï¯ºº×ÛºÏÕ÷ ?y>ji1
¶þ¡¢Ìî¿Õ£º1¡¢ÁÙ´²Õï¶Ï·Î½áºËʱ£¬Ó¦°üÀ¨ ¡¢ ¡¢ ¡¢ Ëĸö²¿·Ö¡£ 2¡¢Ñ󵨻ÆÀàÒ©ÎïËØÐÔ·´Ó¦µÄÁÙ´²±íÏÖÓÐ ¡¢ ¡¢ ¡£ 3¡¢¸ÎÓ²»¯ÉÏÏû»¯µÀ³öѪµÄ²¡ÒòÓÐ ¡¢ ¡¢ ¡£ 4¡¢ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ£¨DIC£©µÄÁÙ´²±íÏÖÓÐ ¡¢ ¡¢ ¡¢ ¡£5¡¢ÈÜѪÐÔÆ¶ÑªÊ±ºìϸ°û´ú³¥ÐÔÔöÉúµÄ±íÏÖÓÐ ¡¢ ¡¢ ¡£ 6¡¢ËáÈÜѪÊÔÑ飨HamÊÔÑ飩ÑôÐÔ¿ÉÒÔÕï¶Ï £¬ÓÃÓÚÕï¶Ï²¢¼ø±ðѪÓѲ¡ÀàÐ͵ÄʵÑéÊÒ¼ì²éÊÇ ¡£ 7¡¢ÉÙÄòÊÇÖ¸ £¬ÎÞÄòÊÇÖ¸ 8¡¢Éö×ÛºÏÕ÷µÄ²¢·¢Ö¢ÓÐ ¡¢ ¡¢ ¡¢ ¡£ 9¡¢¼±¿¯ÐÔÉöÑ׵IJ¡ÀíÑÕ÷Ϊ ¡¢ÔçÆÚΪ £¬ºóÆÚΪ ¡£ 10¡¢¼±ÐÔÓлúÁ×Öж¾Ö÷ÒªÁÙ´²±íÏÖÓÐ ¡¢ ¡¢ Èý¸ö·½Ãæ¡£ 11¡¢¿¹¼××´ÏÙÒ©Îï³£ÓõÄÊÇ À࣬Æä×÷ÓûúÖÆÊÇ ºÍ ¡£ 12¡¢ÌÇÄò²¡ÍªÖ¢ËáÖж¾²¹¼îÖ¸Õ÷Ϊ »ò ¡£ 13¡¢ÄâÅųýÊȸõϸ°ûÁöÒýÆðµÄ¸ßѪѹ£¬Ó¦×ö ʵÑéÊÒ¼ì²é°ïÖúÕï¶Ï¡£ u,8)M'UU
Èý¡¢¼ò´ðÌ⣺1¡¢¼òÊö½áºËÐÔÐØÄ¤Ñ×ÐØË®ÌØµã¡£ 2¡¢¼òÊöÕó·¢ÐÔÊÒÉÏÐÔÐ͝¹ýËÙµÄÖÎÁÆÔÔò¡£ 3¡¢¼òÊö¸ÎÐÔÄÔ²¡µÄÖ÷ÒªÕï¶ÏÒÀ¾Ý¡£ =L#&`s@)_
T=-UcF
ÄϾ©Ò½¿Æ´ó99ÄêÉñ¾²¡Ñ§ \v-I<"::
1.¡¢ÊÔÊö²¡¶¾ÐÔÄÔÑ׵ıíÏÖ£¿ ¶þ¡¢ÊÔÊöСÄÔ²¡±äµÄÁÙ´²±íÏÖ£¿ Èý¡¢ÊÔÊöÄÔðÞµÄÁÙ´²±íÏÖ£¿ 3¡¢Ãû´Ê½âÊÍ 1.¸Ð¾õÐÔʧÓï 2¡¢±È¸¥×ÛºÏÕ÷ sv%E5@
QjSWl,{
$D
ºÓ±±Ò½¿Æ´ó2001ÄêÉñ¾²¡Ñ§ÊÔÌâ LhAW|];
Ò».ÖÜΧÉñ¾¼²²¡»ù±¾²¡Àí±ä»¯Óм¸ÖÖ?²¢¼ÓÒÔ˵Ã÷ ¶þ.¼òÊöÖëÍøÄ¤ÏÂÇ»³öѪµÄÖ¢×´,ÌåÕ÷ºÍÖÎÁÆÔÔò,²¢¾Ù³öÈýÖÖ³£¼û²¡Òò? Èý¡¢ÖØÖ¢¼¡ÎÞÁ¦·¢²¡ÔÀí?ºÎν¼¡ÎÞÁ¦Î£Ïó¼°µ¨¼îÄÜΣÏó?Èç·¢ÉúÉÏÊöÁ½ÖÖΣÏóÈçºÎ´¦Àí? ËÄ¡¢ºÎνÄÔĤ´Ì¼¤Ö¢?¾Ù³ö³ýÄÔĤÑ×Ö¢ÒÔÍâµÄÈýÖÖ¼²²¡? Îå.¼òÊöÇÅÄÔСÄÔ½Å×ÛºÏÖ¢ÁÙ´²±íÏÖ?Áù¡¢ºÎν±ÕËø×ÛºÏÖ¢? Æß.ÉÏʧñ¼ÑªË¨Ðγɲ¡Òò¼°ÁÙ´²±íÏÖ? Psx"[2iZm
rMIX{K)'f
2005ÄêÖÐɽҽ´ó²¡ÉúÊÔÌ⣺ d]sqj\Q57
Ò»£¬Ãû´Ê½âÊÍ£º 3^wHL:u
1¡£·ÎÐÔÄÔ²¡(Ó¢ÎÄ) ?/MkH0[G =
2¡£·ÇÉÙÄòÐÍARF rG~W=!bj
3¡£µòÍö(Ó¢ÎÄ) E<-W & a }
4¡£¹ýÈÈ(Ó¢ÎÄ) +-;v+{
¶þ£¬ÎÊ´ðÌâ l]&A5tz3
1¡£ÊÔÊöÓ¦¼¤·´Ó¦Ê±ÏÂÇðÄÔ-´¹Ìå-ÉöÉÏÏÙ¼¤»îµÄÉúÎïѧЧӦ(ÀûÓë±Ö) vA:ZR=)F
2¡£Êö¸ÎÐÔÄÔ²¡Ê±°±»ùËáʧºâµÄÔÒòºÍÒýÆð¸Î»èÃԵĻúÖÆ¡£ SbX^DAlB1
3¡£ÎªºÎ¸ïÀ¼ÊÏÒõÐÔ¾ú¸ÐȾÒ×ÒýÆðDIC bQI :N
4¡£ÍíÆÚÐÝ¿ËÒýÆðºôÎüË¥½ßµÄ»úÖÆ a'Cny((
1t/c@YUTy
ÄÏ·½Ò½¿Æ´óѧ2005ÃâÒßÌâ $~:ZzZO
1ÒìÊÈÐÔ¿¹Ô Ĥ¹¥»÷¸´ºÏÌå ·Ö×ÓÄ£Äâ ϸ°ûÒò×Ó ¹²´Ì¼¤Òò×Ó Õ³¸½·Ö×Ó Ä£Ê½Ê¶±ðÊÜÌå SmIg HLA Westenbloting V}<<?_
2\ÃâÒßµÄÏÖ´ú¸ÅÄîÊÇʲô£¿ÈçºÎÀí½âËüµÄË«ÖØÐÔ£¿
MwQtf(_
3.ϸ°ûÒò×ӵĹ²Í¬ÌØÕ÷£¿ÓÐÄÄЩÖ÷ÒªµÄ ÉúÎïÑ§ÌØÕ÷£¿ -tWxBGSa@
4.CD4+ Th1¡¢Th2ÔÚÃâÒßÓ¦´ðÖеÄ×÷Óã¿ 9.dZA9l@g
5.ÃâÒßÄÍÊÜ¡¢ÃâÒßÒÖÖÆºÍÃâÒßȱÏݵÄÒìͬµã£¡ EmUt/]
6.¾ö¶¨¿¹ÔÃâÒßÔÐÔµÄÒòËØÓÐÄÄЩ£¿Êµ¼ùÖÐÈçºÎÖÆ±¸¸ßЧ¼ÛµÄ¿¹Ì壿 J_&cI%.
7.¾ÙÀý˵Ã÷È˹¤ÃâÒߵķ½·¨£¬¼òÊöÆäÔÚ¼²²¡·ÀÖÎÖеÄ×÷Óú͵ØÎ»£¿ t OnOzD
8.¿¹¸ÐȾÃâÒßÖУ¬ÌìÈ»ÃâÒßÓë»ñµÃÐÔÃâÒßÊÇÈçºÎÅäºÏ¡¢Ï໥²¹³ä£¿ T7ShE-X
#+6j-^<_6
2005ÄêкͲ©Ê¿ÃâÒßÊÔÌ⣨רҵ»ù´¡£© Vo{
~D:)
µÚÒ»²¿·Ö¸÷רҵ¹«¹²ÊÔÌâ Õ¼70·Ö ;dZZOocV1
1 Åж϶Դí 8%4v6No&*
2 Ìî¿Õ A6_ER&9$>N
µ¥Á´¿¹ÌåÊÇ£¨ £©ºÍ£¨ £©Á¬½Ó£¬ÊôÓÚ£¨ £©¿¹Ìå gJwX
ÃâÒß¼àÊÓ¹¦ÄܵÍÏÂÒ×·¢Éú£¨ £© G
DBV
ÇáÁ´·ÖΪ£¨ £©£¨ £©ÐÍ A9Ea}v9:
²úÉúͬÖÖÐÍ¿¹ÌåÓ㨠£©¶¯ÎïÃâÒß v%`k*n':
¿¹Ìå¶àÑùÐԵIJúÉúÔÒò£¨ £©£¨ £©£¨ £© 9(=+OQ6
ÃâÒßÓ¦´ðµÄ²úÉú½×¶Î£¨ £©£¨ £©£¨ £© w"M!**bP
3 Ñ¡Ôñ WQw11uMt@q
4 Ãû´Ê½âÊÍ10·Ö Zg= {
LAK £¬ Ö×ÁöÏà¹Ø¿¹Ô£¬TCR£¬ÁöÃ磬J chain¡£ <Cs
9$J
5 ¼ò´ðÌâ8·Ö 56C'<#
²¹ÌåµÄÉúÎïѧ»îÐÔ P%w!4v~"
g(jn
/Cx
µÚ¶þ²¿·ÖΪ¸÷¸öרҵµÄÊÔÌâ30·Ö hQzT
=0
Éö²¡×¨Òµ±Ø´ðÌâ +m}D.u*cp
1 ÂýÐÔÒÆÖ²ÅųâµÄ¸ÅÄӰÏìÒòËØ£¬·ÀÖη½·¨15·Ö %I
D48_>*
2 ÀÇ´¯ÉöÑ׵ķ¢²¡»úÀí15·Ö 5K|`RzZ`B$
]U4C2}u
·çʪ²¡×¨Òµ±Ø´ðÌâ f0g_Gn $
1ÊɾúÌ忹Ìå¿âµÄ¹¹½¨ :%fnJg(
2 ÃâÒßÇòµ°°×¹¦ÄÜÇøµÄ×÷Óà ms&5Bq+9
3 ÍüÁË ffOV7Dxy
4
;6,h6a
¸¾¿Æ±Ø´ðÌâ GIkVU6Q}
ճĤÃâÒßϵͳ Aba%QQQ
|F=.NY
2005Äêͬ¼Ã²©Ê¿ÈëѧÕï¶ÏÌâ lH,/N4r*&
Ò» Ãû´Ê½âÊÍ£¨3`X 5£© C1YH\X(r
1. PCR 2R3)/bz-SV
2. Urin Osmol dZd]p8
3. Velcro†ªÒô e/)Vx'd
`+
4. S2¹Ì¶¨·ÖÁÑÒô 7;#o?6!7
5. Standard bicarbonate ]>+ teG:4
|t58n{V.O
¶þ ÎÊ´ðÌâ 6D4u?P,
1. ²»Í¬Çé¿öϸ¹±Ú¾²ÂöÇúÕŵķ½Ïò¼°±æ±ð¸¹±Ú¾²ÂöÇúÕÅÀ´Ô´µÄ·½·¨¡£ \gir
2. ÊæÕÅÆÚ±¼ÂíÂɵÄÌýÕïÌØµã¼°ÆäÓëÉúÀíÐÔµÚÈýÐÄÒôµÄÇø±ð¡£ =@;\9j
3. ¼±ÐÔǰ±ÚÐĹ£ÐĵçͼµÄÑݱä¹ý³Ì¼°ÌØÕ÷¡£ c5eimA%`
4. ²¡Àí·´ÉäµÄ¸ÅÄî¼°ÄÚÈÝ¡£ SmP&wNHQf
5. LDLÖÂASµÄ»úÖÆ¡£ `4|:8@,3{
6. Å®£¬30Ë꣬·¢ÈÈ¿ÈËÔ¡¢¹Ø½ÚÍ´Ò»¸öÔ¡£Ìå¼ì£º38¶È£¬Ë«Ã沿µûÐκìɫƤÕ˫·ÎºôÎüÒô¼õÈõ£¬ÐØÆ¬Ê¾Ë«²àÐØÇ»»ýÒº£¬ÄòPro +++,¹ÜÐÍÄò¡£ DL '{
rK
1£©×î¿ÉÄܵÄÕï¶Ï +4]f6Zz({
2£©ÎªÃ÷È·Õï¶ÏÊ×ѡʵÑéÊÒ¼ì²é lxLEYDGFS
3£©¼ÙÉèÕï¶Ï³ÉÁ¢£¬¶ÔÕï¶Ï×î¾ß¼ÛÖµµÄʵÑéÊÒ½á¹û¡£ FCt %of#
7. ÄУ¬27Ë꣬ÑáÓͰ鷦Á¦£¬ÄɲƤ·ô»ÆÈ¾Ò»ÖÜ£¬°éºÚ±ãÄòÉÙ£¬ÒâʶÕϰÁ½Ìì¡£²éÌ壺ÉñÖ¾²»Ç壬Ƥ·ô¹®Ä¤»ÆÈ¾£¬È«ÉíÉ¢ÔÚðö°ß£¬Íܸ¹£¬³¦ÃùÒô¼õÈõ¡£ AHP;N6Y6
1£©×î¿ÉÄܵÄÕï¶Ï n8) eC2A
2£©´ËʱÊ×Ñ¡½øÐиÎÔà´¥ÕïµÄ·½·¨¼°¼ì²é½á¹û l4E0/F
3£©×îӦѡÔñµÄ¸Î¹¦Äܼì²éÏîÄ¿¡£ Q,>]f@m
8. ÄУ¬60Ë꣬·´¸´¿ÈËÔ¿È̵´Æø20Ä꣬ÔÙ·¢Á½ÖÜסԺÖÎÁÆ£¬¾¿¹¸ÐȾ¡¢½â¾·¡¢Æ½´ÖÎÁÆÓÐËù»º½â£¬×òÍíÍ»·¢ÐØÃÆ£¬ºôÎüÀ§ÄÑ¡£Ìå¼ì£º¶Ë×øÎ»£¬¿Ú´½·¢ç¤¡£Çë·ÖÎö eC$ Jdf
1£©¸Ã²¡ÈË×îÓпÉÄܵÄÕï¶Ï u5P2*
2£©È·ÕïËùÐèµÄÊ×Ñ¡¼ì²é y>JSo9[@
3£©¼ÙÉè¸ÃÕï¶Ï³ÉÁ¢£¬Æä×î¾ßÕï¶Ï¼ÛÖµµÄÑôÐÔÌåÕ÷¡£ MB?762Q
h`MTB!o
2005É϶þÒ½²©Ê¿·Ö×ÓÉúÎïѧ£¨×¨Òµ»ù´¡£© ^#z*
ÈýÁ´DNA ;<K#h9#*7
ת»ùÒò¶¯Îï z
dUSmb
IP3 5oY^;)\/
Ãû´Ê½âÊÍ ,D{D
QJ(B
±í´ïÐòÁбêÇ© 6"U$H$
i.G
»îÐÔëÄ u_%L~1+'
Äæ×ªÂ¼Ã¸ EpH\;25u
ÖÎÁÆÐÔ¿Ë¡ FWQNO(
¶ËÁ£Ã¸ p) m0\
ÔÓ½»×èÖÍ·Òë %_ Vj'z~T
run off transcription E Ks4N4k
µòÍöµ°°× V\r2=ok@y
ÎÊ´ð ;0:[X+"(
DNA¸´ÖƵĹý³Ì 9 EV. ![
ºËµ°°×ÌåÔÚµ°°×ºÏ³É×÷Óà 7NQEn Al
Äý½º¹ýÂ˲ãÎöµÄÓ¦ÓýøÕ¹ %bgUU|CdA
;^|:*
2005ÄêÉ϶þÒ½²©Ê¿Éú»¯¿¼Ìâ OCbwV7q:
Ãû´Ê½âÊÍ DDp\*6y3l
Ѫ½¬¹¦ÄÜø h=MEQ-3jg
Gµ°°× $VUX?ii$7=
·Ö×Ó°é +Z=DvKsT
J
LCAT .%
+y_.l
¼ò´ð &O^t]7
¸ÎÔàËðÉË·²µÇ°×Ë«ÑôÐÔ»úÖÆ u\o~'Jz
ÎÊ´ðÌâ e#z#bz2<
»ùÒòÕï¶ÏµÄ·½·¨£¬¾ÙÀý V5bB$tL}3
ѪNH3µÄÀ´Ô´È¥Â· v8
pOA<s
TRNA¶þ¼¶½á¹¹Ìصã×÷Óà "{M?,jP#
ΪʲôÌÇÉãÈ¡¹ý¶à»á·ÊÅÖ i&\cDQ 3
ÐźŴ«µ¼Í¨Â· g0:{{w
6Á×ËáÆÏÌÑÌÇ£¬¼ºÌǼ¤Ã¸£¬±ûͪËáÔÚÎïÖÊ´úлΪÊàŦµØÎ»µÄÔÒò Jqz K5)
DNA±àÂëÐòÁÐÒ»¸öbpµÄÍ»±äÓÐʲôºó¹û£¿¾ÙÀý˵Ã÷ WSOz^]
nXfdf-
ÄÏ·½Ò½¿Æ´óѧ2005ϸ°ûÉúβ©ÊÔÌâ *b\&R%6dR
1.ÊÜÌå½éµ¼µÄÄÚÍÌ×÷ÓõĹý³ÌÒÔ¼°Ìص㣿 OzAxnd\.N
2.ϸ°û¼äÓм¸ÖÖÁ¬½Ó·½Ê½£¬ÆäÖÐÄÇÖÖ¾ßÓÐϸ°ûͨѶ×÷Óã¬ÒÔ¼°ÎªÊ²Ã´£¿ g,s^qW0vds
3.³ÉÊì´Ù½øÒò×ÓµÄ×é³ÉÒÔ¼°ÔÚϸ°ûÖÜÆÚµ÷¿ØÖеÄ×÷Óã¿ ZMO ym=
4.ϸ°ûÖÜÆÚµ÷¿ØµÄÑо¿·½·¨£¿ eR:
C?v
5.ÔÚ·Ö×ÓºÍϸ°ûˮƽÉ϶Ôϸ°ûË¥ÀϸÅÄî½øÐвûÊö£¿ )_SpY\J
ÔºËÉúÎïDNA¾ÛºÏø3ºÍRNA¾ÛºÏøµÄÌØµã {fS~G2@1
cr ~.],$Om
2005Ä긴µ©´óѧ·ÅÁÆ¿¼²©ÊÔÌâ % !Ih=DZ
·ÅÉäÖÎÁÆÑ§(רҵ¿Î) KRb'kW
1. ÏÖ´úÖ×Áö·ÅÉäÖÎÁÆÁ÷³Ì CI^s~M >
2. ÈçºÎ±£Ö¤°ÐÇø¹´»µÄÒ»ÖÂÐÔºÍ׼ȷÐÔ LpN3cy>U
3.ºí°©·ÖÐͺÍÖÎÁÆÔÔò PP8627uP
4. Ìá¸ß·ÇСϸ°û·Î°©ÁÆÐ§µÄ·ÅÉäÖÎÁƼ¼Êõ fw)Q1"|
5. ×ÛºÏÖÎÁƵÄÖØÒªÐÔ
)
(0=w4
Ö×Áöѧ(רҵ»ù´¡) Tb\<e3Te_
1.Ãû´Ê½âÊÍ @S1Z"%S
ÓÀÉú»¯ µ¥ºËÜÕËá¶à̬ÐÔ ½»½çÐÔÖ×Áö ²»µäÐÍÔöÉú @;}vK=6L
2. ÂÛÊöÌâ st)qw]Dn;Y
2.1 ϸ°û¶ñ±ä WaSZw0U}y
2.2 ¶à»ùÒòÒÅ´«²¡Ìصã J;'H],w}f
2.3 ÒÖ°©»ùÒò¸ÅÄîºÍÒÖ°©»úÖÆ fGoJP[ae
2.4 Î¢×ªÒÆ¸ÅÄîºÍÁÙ´²ÒâÒå K%1`LT5:~
2.5 µòÍöÆÕ±éÉúÎïѧÒâÒå izs=5
YP>J'{?b*"
2001ͬ¼ÃÒ½¿ÆÔºÉñ¾½âÆÊѧÊÔÌâ OAf}\
J vq)%t8q>
Ò»Ãû½â£º1´óÄÔ¶¯Âö»· 2Ö²ÎïÉñ¾ÏµÍ³ 3 internal capsule 4 choroid plexus '3?-o|v@D
wV-9T*QrM
¶þÎÊ´ð£º1¡£´©¾º£Ãàñ¼µÄÄÔÉñ¾ÓÐÄÄЩ£¿·Ö±ð¼òÊöËüÃǵķֲ¼ "RgP!
a(X V~o
2¡£¼¹ËèÄÚ±¡Êø£¬Ð¨Êø£¬¼¹ËèÇðÄÔ²àÊøºÍƤÖʼ¹ËèÊøµÄλÖã¬ÆðÖ¹ºÍ¹¦ÄÜ 6Ta+f3V
m|
3Q'
3¡£ÄÔÉñ¾£¨Â²¿£©µÄ¸±½»¸ÐÉñ¾½ÚÓÐÄÄЩ£¿Æä½ÚǰÏËά·Ö±ðÆð×Ժ䦣¿½ÚºóÏËά·Ö²¼µ½ÄÄÀï¡£ u;+8Jg+xH/
FmSE]et
4ij»¼ÕßÍ·²¿ÓÒ²àò¨ÇøÊÜËðÉ˺óÁ½Ð¡Ê±×óÓÒ£¬Í»È»»èµ¹£¬ËÍÒ½Ôº¼ì²é·¢ÏÖ£º£¨1£©ÓÒÍ«¿×É¢´ó£¬Ö±½ÓºÍ¼ä½Ó¶Ô¹â·´ÉäÏûʧ£¬ÓÒÑÛíúÏ´¹£»£¨2£©×óÉÏ£¬ÏÂÖ«²»Äܻ£»£¨3£©×óÏ¥·´É俺½ø£¬×ãèÏ·´ÉäÑôÐÔ¡£Õï¶ÏΪӲĤÍâѪÖײ¢·¢Ð¡ÄÔÄ»ÁÑ¿×ðÞ¡£ÊÔ·ÖÎö£º£¨1£©ËðÉËÁËʲôѪ¹Ü£¿¸ÃѪ¹ÜÆðÓں䦣¿¾ºÎ´¦È룿£¨2£©ÖðÒ»½âÊͳöÏÖÉÏÊö3×éÖ¢×´£¬ÌåÕ÷µÄÔÒò¡£ 9sI&d
]-_ ma
2000 W8F@nY
-fp/3-
Ò»Ãû½â NY|hE@{2.
1ÄÔÆÁÕÏ 2×¶ÌåÍâϵ 3 Ö²ÎïÉñ¾Ïµ 4ÄÚÄÒ r6GXmr
&hrMpD6z6i
¶þÎÊ´ð +s^nT{B@\
1¡£ ëè¹Ç¾±¹ÇÕÛÒ×ËðÉËÄÄÌõÉñ¾£¬³öÏÖÄÄЩ֢״£¬ÌåÕ÷£¬ÎªÊ²Ã´£¿ 2|ej~}Y
e N v\ZR1
2¡£¼òÊöÄԵ͝ÂöÀ´Ô´¼°¹©Ñª·¶Î§ Mdq|:^px
'#SZ|Rr6tX
3¡£Ð¡ÄÔÄ»Çм£ðÞÓëÕí¹Ç´ó¿×ð޵ĽâÆÊѪ»ù´¡£¬»á²úÉúÄÄЩºó¹û Jg)( F|>o
mE_%
4¡£ÊÔÊöƤÖʺËÊø ~!=Am:-wr
M
V2$0
1999 :!hO9ho
?8/r=
Ò»Ãû½â )Ly~\*
1ÎÆ×´Ìå 2°×½»Í¨Ö§ 3 ÏËÎ¬Êø 4¶¥¸ÇÇ°Çø
;u[:J
q%QvBN
¶þÎÊ´ð u}
)*6 l.
1¡£ÊÔÊöÐØÉñ¾Ç°Ö§µÄ½Ú¶ÎÐÔºËÖØµþÐÔ Ijap%l1I
-2!S>P Zs
2¡£ÄÚÄÒËðÉËʱΪʲô»á³öÏÖ¡°ÈýÆ«×ÛºÏÕ÷¡±£¿ #Hz9@
H
kvuRT`/
3¡£ÊÔÊö×µ£»ùµ×¶¯Âöµ×Ðг̣¬·ÖÖ§ºÍ·Ö²¼£¿ egBk7@Ko
?@Q0;LG
4¡£¼¹ËèÐØ7ÓÒ°ìËðÉËʱ»¼Õß»áÓÐÄÄЩ¸Ð¾õ£¬Ô˶¯Õϰ£¿¼òÊöÆäÔÒò *C0a,G4
'wtb"0 }
1998 ij#v_~g3
Ò»Ãû½â CM$&XJzva
1¡£»ùµ×ºË 2¡£´óÄÔ¶¯Âö»· 3 ÄÔÊÒÂöÂç´Ô 4Ç£ÉæÐÔÍ´ 5б·½Ìå 7)[2Ud8
{[`(o
0@(
¶þÎÊ´ð QlV(D<
1¡£ÔÚ´óÄÔÆ¤ÖÊ»úÄܶ¨Î»ÖУ¬µÚÒ»ÇûÌå¸Ð¾õÇøÎ»Óں䦣¬ÉíÌå¸÷²¿ÔÚ´ËÇøµÄͶӰÓкÎÌØµã \At~94
>N 2kWSa
2ÉÏÏÂÔ˶¯Éñ¾ÔªËðÉ˵ÄÖ¢×´ÓëÌåÕ÷Óкβ»Í¬£¬ÎªÊ²Ã´£¿ tu"-]^
(9ZW^flY
3Õë´ÌÓÒÊÖСָƤ·ô TH1Éñ¾Ö§ÅäÇøºóÍ´¾õ³å¶¯¾ºÎ;¾¶´«Èë´óÄÔ /4OQx0Xmm
FyWf`XTO
4ëõÉñ¾µÄ×é³É£¬Ðо¶ºÍ·Ö²¼ jA;b2A]G
9M'"q7Kh
5¼¹Ëèǰ½Çϸ°ûµÄÀàÐͼ°Æä¹¦ÄÜ fZr{x$]N0
Te~jYkCd
1997 TTl9xs,nO
Ò»Ãû½â p7Zeudmj
1¡£Ð¡ÄÔºË 2¡£ÄÔ¸ÉÍø×´½á¹¹ 3 ÖëÍøÄ¤Á£ 4 ÄÚ²àÇðϵ½»²æ @(oY.PeS<z
¶þÎÊ´ð PX_9i@ZG
1¡£ÊÔÊöÉàµÄÉñ¾Ö§Åä¼°Æä×÷Óà Og1\6Q
2¡£´¹ÌåÖ×ÁöѹÆÈÊÓ½»²æºó»¼ÕßµÄÊÓ¾õÓкÎÕϰ£¬ÎªÊ²Ã´?Çëͬʱд³öÊÓ¾õ´«µ¼¾¶Â· "%+||IyW
3ëŹÇÍâ¿Æ¾±¹ÇÕÛ£¬ëŹÇÖжιÇÕÛºÍëŹÇÄÚÉÏ÷Á¹ÇÕÛʱ£¬¸÷Ò×ËðÉËÄÇÌõÉñ¾£¬ëŹÇÍâ¿Æ¾±¹ÇÕ۵ϼÕß³£°éÓÐʲô¹¦ÄÜÕϰ OmZZTeGg1s
4ÁÙ´²ÉϾ¼¹ËèÖëÍøÄ¤ÏÂÇ»´©´Ì³éÈ¡ÄÔ¼¹Òº£¬³£ÔÚ3£4Ñü×µ¼¬Í»¼ä϶´ÌÈ룬Æä½âÆÊѧ»ù´¡ÊÇʲô R[6R)#o
Q?LzL(OioN
1996 l l*g *zt3
ÎÊ´ð
:|S[i('
1¡£ÊÔÊö¹ÄË÷µÄÏËά³É·Ö£¬Ðг̷ֲ¼Ó빦ÄÜ Z L0k
2£¬ÓÐÄÄЩÉñ¾·Ö²¼ÖÁÊÓÆ÷£¬Çë·Ö±ð¼òÊöËüÃǵÄÐÔÖÊ£¬·Ö²¼ºÍ¹¦ÄÜ ujE~#b}X
3¡£Ð¡ÄÔ±âÌÒÌåλÓں䦣¬ÇëÓýâÆÊѧ֪ʶ½âÊÍСÄÔ±âÌÒÌåðÞ·¢ÉúµÄ»úÀíºÍÑÏÖØºó¹û UtJfO`m9P
4£¬ÊÔÊöµÚËÄÄÔÊÒµÄλÖ㬹¹³ÉºÍ½»Í¨ 0S; Ipg
5¡£ëè×ÜÉñ¾ËðÉ˺÷¢Óںβ¿Î»£¬ÊÜËðʧºóÓÐÄÄЩÖ÷Òª±íÏÖ£¬ÎªÊ²Ã´£¿ 2?Ryk`2i)
6¡£ÄÚÄÒÏ¥²¿Í¨¹ýÄÄЩ´«µ¼Êø£¬ÆäËðÉ˺óÓÐÄÄЩÖ÷Òª±íÏÖ£¬ÎªÊ²Ã´£¿ "QS(4yw?jg
7¡£ÊÔÊöÄÚÔà´ó£¬Ð¡Éñ¾µÄÆðÔ´£¬ÁªÏµ¼°½ÚºóÏËά·Ö²¼¸Å¿ö \24'iYtqW
I]5){Q"S
1995
6tP!(
Ò»Ãû½â .Wp(@l'Hd
1¡£±¾Ìå¸Ð¾õ 2¡£Éñ¾ºË 3¡£¹ÌÌåÊø 4¡£ëÝíûÌå s0vcGh#w
¶þ¡£ÎÊ´ð MFO%F) 5
1¡£ÔÚÄԸɸ½×ÅÓм¸¶ÔÄÔÉñ¾£¬ËüÃǸ÷ÊôºÎÐÔÖÊ£¬¸÷º¬¼¸ÖÖÏËά³É·Ö£¬²¢·Ö±ðд³öËüÃÇµÄÆðʼºË»òÖÐÖ¹ºË ,K6ODtw.
2¡£ÈÝÒ׺ϲ¢èãÉñ¾ËðÉ˵ÄëŹǹÇÕÛ³£·¢ÉúÔÚʲô²¿Î»£¬¸ÃÉñ¾ËðÉ˺óÓкÎÔ˶¯Óë¸Ð¾õÕϰ£¬ÎªÊ²Ã´ hU
p3$4w
3¡£½»¸ÐÉñ¾Ó븱½»¸ÐÉñ¾µÄÖ÷񻂿±ðÔÚÄÄÀï i@WO>+iB
4ÓҲදÑÛÉñ¾ÊÜËðÉËʱ£¬ÓÒÑÛÍ«¿×Ö±½Ó¶Ô¹â·´ÉäÓë¼ä½Ó¶Ô¹â·´ÉäµÄ±íÏÖÈçºÎ£¬ÎªÊ²Ã´£¬Ç뽫¸Ã·´É侶·һһÁгö ? N]bFW"t|
bT9:9LP
1994 ^mI`P}5Y
x~8R.Sg
Ò»Ãû½â +JD^5J,-NJ
1¡£Ç£ÉæÐÔÍ´ 2¡£×¶ÌåÍâϵ 3ÄÔÆÁÕÏ yJqDB$0
Qd% (]L[N.
¶þÎÊ´ð l,A\]QDvl
1¡£ÄÄЩÄÔÉñ¾Öк¬Óи±½»¸ÐÉñ¾ÏËά£¬·Ö±ðд³öËüÃǵĽÚǰÉñ¾ÔªÃû³ÆºÍλÖÃÒÔ¼°½ÚºóÏËάµÄ·Ö²¼ a04S&ez
j
AlrUfSBB
2¡£ÔÚ´óÄÔÆ¤ÖÊ»úÄܶ¨Î»ÖУ¬µÚÒ»ÇûÌåÔ˶¯ÇøÎ»Óں䦣¬ÉíÌå¸÷²¿ÔÚ´ËÇøµÄͶӰÓкÎÌØµã "].TKF#yg
z=jzr=lP
3¡£ÒÀ¾ÝСÄԵĽø»¯¹ý³Ì£¬Ð¡ÄÔ¿É·Ö¼¸²¿£¬¸÷²¿µÄ·¶Î§ºÍ¹¦ÄÜÈçºÎ e2;=OoBK
\B/( H)Cd*
4¡£¾±´ÔµÄ×é³É£¬Î»Ö㬷ֲ¼¼°¸÷Ö÷ҪƤ֧µÄÃû³ÆºÍdz³ö²¿Î» WwSyw?T
;tD?a7
5¡£×ÛÊöÄÔµÄѪҺ¹©Ó¦£¬°üÀ¨Ö÷Òª·ÖÖ§µÄ·Ö²¼ºÍ´óÄÔ¶¯Âö»· X88I|Z'HIh
Cd p_niF
1993 d]=>U
^K
u6\W"LW
Ò»Ãû½â &|zV Wl
1£¬´óÄÔ¶¯Âö»· 2¡£·´É仡 3¡£ÎÆ×´Ìå 4¡£Ð¡ÄÔÈý¶Ô½Ç 5¡£ÄÚÄÒ waV4~BdL
G
jrN1+9=
¶þ¡£ÎÊ´ðÌâ j=>WWlZ
c1f`?i}.
1£¬ÄÔ¼¹ÒºµÄ²úÉúºÍÑ»· Pc~)4>X<
E/ku VZX
2¡£×ó²àƤÖʺËÊøÊÜËðËùÒýÆðµÄÃæ¼¡Ì±»¾ÓëÓÒ²àÃæÉñ¾ÖÜΧÐÔËðÉËËùÒýÆðµÄÃæ¼¡Ì±»¾ÓÐÎÞÇø±ð£¬ÎªÊ²Ã´£¿ A#79$[>w
bV@5B#] 2R
3Í«¿×¶Ô¹â·´ÉäµÄ;¾¶ gp{P _
=&U7:u
4ÊÖµÄÉñ¾Ö§Åä kRz qgVr%
0j'k%R[l
2001Äê G{|FV
m
1. ÄÔÉñ¾III¡¢VII¡¢IX¡¢XµÄÆðºË¡¢Öպˡ¢ÏËά³É·Ö¡¢Éñ¾Ðг̡¢·ÖÖ§·Ö²¼¼°¹¦ÄÜ¡£ 8ax3"G
2. ×¶ÌåϵµÄ´«Í³¸ÅÄî¼°ÐÞÕý¡£ !un_JZD
3. ¹¹³É×¶ÌåÍâϵµÄÖ÷Òª½á¹¹¡¢Éñ¾Í¨Â·ºÍ¹¦ÄܸÅÄî¡£ QV%eTA
4. º£Âí½á¹¹µÄϸ°û¹¹Öþ£¬Ö÷ÒªÏËάÁªÏµºÍ±ßԵϵͳµÄ¹¦ÄÜ¡£ RveMz$Yy
5. 5-HTÄÜÉñ¾ÔªÔÚÄÔÄڵķֲ¼¡¢Éñ¾Í¨Â·¡¢Ö÷ÒªÊÜÌå·ÖÐͺͶàÖÖÉñ¾¹¦ÄÜ¡£ =Sn!'@%U]
6. ¶à°Í°·ÄÜÉñ¾ÔªÔÚÄÔÄڵķֲ¼¡¢Éñ¾Í¨Â·¡¢ÊÜÌå·ÖÐͺ͹¦ÄÜ¡£ UC9w T
}KrZ6cG9#
Ò»¡¢ Ãû´Ê½âÊÍ Tq >?.bq9
1¡¢ BaylissЧӦ2¡¢WernickÄÔ²¡3¡¢WernickʧÓï4¡¢Tolosa-Hunt×ÛºÏÕ÷5¡¢Collet-Sicard×ÛºÏÕ÷ Dr"F5Wbg
¶þ¡¢ Ìî¿Õ !1?Nc}T0Q&
1¡¢ ×é³ÉѪ¹Ü×èÁ¦µÄÒòËØÓÐ_¡¢_¡¢_¡¢¼°__µÈ¡£
#1f8A5<
2¡¢ µ÷½ÚС¶¯ÂöÕÅÁ¦µÄÒòËØÓÐ_¡¢_¡¢_¼°_µÈ¡£ +f?xVW<h
Èý¡¢ Ñ¡ÔñÌâ 4,R1}.?BzJ
1¡¢ Ò»ÀýÄÐÐÔ20Ë꣬²éÌå·¢ÏÖÓÒ²à½ÇĤ·´ÉäÁéÃô£¬¼ä½Ó·´ÉäÏûʧ£¬²¡±äÔÚ QGd"Z lQ
AÓÒ²àÈý²æÉñ¾BÓҲදÑÛÉñ¾C×ó²à¶¯ÑÛÉñ¾D×ó²àÈý²æÉñ¾E×ó²àÃæÉñ¾ !Lj+&D|z
2¡¢ Ò»ÀýÄÐÐÔ31Ë꣬1¸öÔÂÀ´×ó²àÉÏ¡¢ÏÂÖ«Âéľ£¬²éÌå·¢ÏÖÓÒ²àÃæ²¿¼°×ó²àÉÏ¡¢ÏÂÖ«Í´¾õ¼õÍË£¬²¡±ä×î¿ÉÄÜÔÚ V0
OT _F
Aºó¸ù Bºó½Ç CÄÔ¸É DÇðÄÔ EÄÚÊø !7[Rhk7bW
3¡¢ Ò»ÀýÄÐ32Ë꣬¾×ÍáÀ´ÕӡÏó×ó²àÃæÉñ¾Ñ×£¬ÏÂÁÐÄĵãÕýÈ· ~4~>;e
A×ó½ÇĤ·´ÉäÏûʧBÓÒÑÛíú±ÕºÏ²»È«CÕÅ¿ÚÏÂò¢Æ«Ïò½¡²àD×ó²àÃæ²¿¸Ð¾õÏûʧE×óÑÛíú±ÕºÏ²»È« !ly]{DTmm
4¡¢ Ò»ÀýÅ®ÐÔ50Ë꣬˫ÑÛÊÓÁ¦Ä£ºý£¬²éË«ÑÛò¨²àÆ«Òô£¬Æä²¡±ä²¿Î»ÔÚ }u..m$h
AÊÓÉñ¾ Bò¨Ò¶ C¶¥Ò¶ DÊÓÉñ¾½»²æ²¿ EÍâ²àÏ¥×´Ìå Nb;Yti@Y.
5¡¢ Ò»ÀýÅ®ÐÔ35Ë꣬×óÑÛ±Õ²»½ô£¬×ó¿Ú½ÇÁ÷ÏÑ£¬×î²»¿ÉÄܵÄÖ¢×´ÊÇ b$ )XS
A×óÑÛÁ÷ÀáB×óÀáÒº·ÖÃÚ¼õÉÙC×ó²àζ¾õ¼õÍËD×ó²àÌýÉùÒô¹ýÏìEÑÀ³Ý¿Ú½Ç×óÆ« 2myHn/%C
6¡¢ Ò»Àý62ËêÈË£¬Í»È»ÓÒ²àÍ·Í´£¬°éŻͣ¬BP:26/18KP£¨195/135mmHg£©ÏÂÁÐÄĸö×î²»¿ÉÄÜ r&ex<(I{
A¶îÒ²³öѪBÄÚÄÒ³öѪCÇðÄÔ³öѪDÄÔѪ˨ÐγÉE¶¹×´ºË³öѪ $
V"7UA22
7¡¢ Ò»ÀýÄÐ68Ë꣬ÕïΪ׵»ùµ×¶¯Âö¹©Ñª²»×㣬ÏÂÁÐÄÄÒ»ÖÖÊôÓڴ˲¡Ö¢×´ u_U51C\rb
AÑ£ÔÎBÑÛÇòÔ˶¯ÕϰC½»²æÐÔÆ«DÍÌÑÊÕϰEʧÓïÖ¢ $
p{Q ]|ww
8¡¢ Ò»Àý33ËêÅ®ÐÔ£¬¸Ðð·¢ÉÕ5Ì죬²¡ºó³öÏÖË«ÏÂÖ«ÎÞÁ¦²¢Öð½¥¼ÓÖØ£¬Æø¶Ì¡¢ÅÅÄòÀ§ÄÑ£¬²¡ºó8ÌìÀ´Õ×îÖØÒªµÄ²¡ÀíÌåÕ÷ÊÇ£º .Su9fjy%
AË«ÏÂÖ«¼¡Á¦Ë«ÏÂÖ«¼¡Á¦I B˫ϥ·´É俺½øCºá¹ßÐԸоõÕϰDË«ÏÂÖ«²¡Àí·´ÉäÑôÐÔEÄòäóÁô Nl1v*9_x
9¡¢ ͬÉÏÌ⣬×îÖØÒªµÄ¸¨Öú¼ì²éÊÇ '4qi^$|\
AÐØ×µÏñ£¨XƬ£©BÄÔ¼¹Òº¼ì²é CÐØ×µCT D¼¡µçͼ EѪÇåÃâÒßÇòµ°°×¼ì²é dKyX70Zy9
10¡¢ ͬÉÏÌ⣬ÄÔ¼¹ÒºÑ¹Á¦Õý³££¬°×ϸ°û20¸ö£¬µ°°×80mg%£¬ÈçºÎ´¦Àí P
A9
]
L
A¾²µÎµØÈûÃ×ËÉB¼¹×µMRI C¾²µÎ¸Ê¶´¼D¾²µÎÉñ¾ÓªÑø¼ÁE¾²µÎ»·±ûɳÐÇ u37@9
ËÄ¡¢ ¼ò´ðÌâ ghiFI<)VY
1¡¢ ¶«·½È˶෢ÐÔÓ²»¯²¡Àí¸Ä±äÓëÎ÷·½ÈËÇø±ðÊÇʲô£¿ ef!V EtEOv
2¡¢ ƤÖÊ¡ªÎÆ×´Ì塪¼¹Ëè±äÐÔÖ÷Òª²¡Àí±ä»¯£¿ R('44v5JQp
3¡¢ ÂýÐÔÖ²Îï״̬ÁÙ´²±íÏÖÓÐÄÄЩ£¿ l>M&S^/s j
4¡¢ ƫͷʹ·¢²¡»úÖÆÊÇʲô£¿ d+fig{<b
5¡¢ È«ÃæÇ¿Ö±-ÕóÂη¢×÷ÖÐðïÐԻ´«²¥¾¶Â·ÊÇʲô£¿ =GjxqIv
Îå¡¢ ÎÊ´ðÌâ
p_QL{gn
1¡¢ Alzheimer²¡Ö÷Òª²¡Àí¸Ä±äÊÇʲô? #f@sq5pTO
2¡¢ ÊÔÊöÖØÖ¢¼¡ÎÞÁ¦µÄ·¢²¡»úÖÆ£¿ R28h%KN
3¡¢ Õð²üÂé±ÔÉú»¯¸Ä±äÊÇʲô£¿ gKS0!U
W 6~B~L
> 2004ÄêÊ×Ò½Éñ¾½âÆÊÌâ fN>o465I6
> Ò»¡¢ Ãû´Ê½âÊÍ£¨Ã¿Ìâ5·Ö£¬¹²60·Ö£© c X553&
> 1¡¢ Ñü÷¾¸É2¡¢½Þ×´Éñ¾½Ú3¡¢¼¹Ëè½Ú¶Î4¡¢çÖºË5¡¢±ßԵϵͳ6¡¢Ç°ÄÔÄÚ²àÊø7.saphenous nerve 8.celiac plexus 9.climbing fiber 10.primary somatic motor area 11.cavernous sinus 6kKIDEX
> 12. tympanic nerve r>`65o
> ¶þ¡¢Ñ¡ÔñÌ⣨2*15£¬1-7Ϊµ¥Ñ¡£¬8-15Ϊ¶àÑ¡£© hM(|d@)
> 1¡¢ Ö§ÅäµÚ¶þò¾×´¼¡µÄÉñ¾ÊÇ H5=-b@(
> A ¼¡Æ¤Éñ¾BÒ¸Éñ¾CÕýÖÐÉñ¾D³ßÉñ¾EèãÉñ¾ [>4Ou^=1
> 2¡¢ Ö§ÅäÈùÏÙ·ÖÃڻµÄÉñ¾ÊÇ :NO'[iE
> AÃæÉñ¾BÈý²æÉñ¾CÃÔ×ßÉñ¾DÉàÑÊÉñ¾E¸±Éñ¾ fXBA
P10#
> 3¡¢ ´óÄÔ´ó¾²Âö×¢ÈëµÄ½á¹¹ÊÇ -mG3#88*
AÉÏʸ״ñ¼BÏÂʸ״ñ¼Cº£Ãàñ¼DÖ±ñ¼Eñ¼»ã qV.*sdS>
> 4¡¢ ÒâʶÐÔÇû¸É¡¢ËÄÖ«Éî¸Ð¾õ´«µ¼Â³µÄ½»²æ²¿Î»ÊÇ q?{wRBVVB
A¼¹ËèBÑÓËèCÄÔÇÅDÖÐÄÔE±³²àÇðÄÔ D'#Wc#b
> 5¡¢ ÄÚÔà´óÉñ¾½»»»Éñ¾ÔªµÄλÖÃÊÇ Rg,pC.7;
A×µÅÔÉñ¾½ÚB׵ǰÉñ¾½ÚCÆ÷¹ÙÅÔÉñ¾½ÚDÆ÷¹ÙÄÚÉñ¾½ÚE¼¹Éñ¾½Ú a4L8MgF&$-
> 6¡¢ ÓëºÚÖÊÓÐÍù·µÏËάÁªÏµµÄ½á¹¹ÊÇ IiIF4 pQ,
AÐÂÎÆ×´ÌåB¾ÉÎÅ×´ÌåCÐÓÈÊÌåDÈéÍ·ÌåEÄÚ²àÏ¥×´Ìå S!k cC-7
> 7¡¢ »¼Õß²»ÄÜÓÃÉìλµÄʳָÓëÖÐÖ¸¼ÐסֽƬ£¬ÊÜËðÉ˵ÄÉñ¾ÊÇ n_hV;
AèãÉñ¾ÉîÖ§BèãÉñ¾Ç³Ö§C³ßÉñ¾ÉîÖ§D³ßÉñ¾Ç³Ö§EÕýÖÐÉñ¾·µÖ§ O[;>Y'zqC%
> 8¡¢ ÓÐÃÔ×ßÉñ¾²ÎÓëµÄÉñ¾´ÓÓÐ Sim\+SL{#
A¾±ÄÚ¶¯Âö´ÔBʳ¹Ü´ÔC·Î´ÔD¸¹Ç»´ÔEÅè´Ô )avli@W-3j
> 9¡¢ Òɺ˷¢³öµÄÏËά¼ÓÈëµÄÉñ¾ÓÐAÉàÑÊÉñ¾BÃÔ×ßÉñ¾C¸±Éñ¾DÃæÉñ¾EÉàÏÂÉñ¾ `TOm.YZG
> 10¡¢ ÓëÉñ¾ÄÚ·ÖÃÚÓйصĺËÓÐAÊÓÉϺËBÈéÍ·ÌåºËCÊÒÅÔºËD©¶·ºËEÊÓ½»²æÉÏºË Y dmYE$
> 11¡¢ ²ÎÓë×é³ÉСÄÔϽŵÄÏËÎ¬ÊøÓÐA¼¹ËèСÄÔÇ°ÊøB¼¹ËèСÄÔºóÊøCéÏéСÄÔÊøDШСÄÔÊøEǰͥСÄÔÊø (5re'Pl
> 12¡¢ ÊôÓÚÄԸɵÄÍø×´½á¹¹µÄºËÍÅÓÐAÐ¨ÊøºËBШÐκËCÐ¨Êø¸±ºËD±ÛÅÔºËEÖзìºË 7g cr$&+e
> 13¡¢ Ð̾¯¼¹ËèÍâ²àË÷ÄÚµÄÏËÎ¬ÊøÓÐA¼¹ËèСÄÔÇ°ÊøB¼¹ËèСÄÔºóÊøCºìºË¼¹ËèÊøDǰͥ¼¹ËèÊøE¶¥¸Ç¼¹ËèÊø :e`;["(,
> 14¡¢ ÊôÓÚ´óÄÔÆ¤ÖÊͶÉäÉñ¾ÔªµÄÓÐA×¶Ìåϸ°ûB¿ÅÁ£Ï¸°ûCËóÐÎϸ°ûDˮƽϸ°ûE Martinotliϸ°û =M)+O%`*6
> 15¡¢ ¹ØÓÚÄÚ²à×ÝÊøµÄÕýÈ·ÃèÊöÓÐAÖ÷ÒªÀ´×ÔǰͥÉñ¾ºËȺBÐÐÓÚ¼¹ËèǰË÷CÏ´ïÑüËèDÖ¹ÓÚ1-4²ãÖмäÉñ¾ÔªEÍê³ÉÍ·¡¢¾±×ËÊÆ·´ÉäÐÔµ÷½Ú nWfOiw-t
> Èý¡¢12*5=60·Ö e-ILUzT
> 1¡¢ ÊÔÊöÑÛµÄÉñ¾Ö§Å䣿 xg k~y,F
> 2¡¢ ÏÂÖ«µÄ±¾Ìå¸Ð¾õÊÇÈçºÎ´«µÝµ½´óÄÔÆ¤Öʵģ¿
@S yGj#
> 3¡¢ ÊÔÊöÒÔϽṹÊÇÈçºÎ·Ö²ãµÄ£¿£¨1£©ÅÔÖÐÑëСҶ£¨2£©ÈÞÇò£¨3£©ÏÂÍÐ V.6h6B!vB
> 4¡¢ ¼òÊöУַÊú뼡µÄÉñ¾Ö§Å䣨°üÀ¨Ðо¶£© %:sQ[^0
> 5¡¢ ÄãÊÇÈçºÎÀí½âÇ£ÉæÐÔÍ´µÄ£¿ _<|NVweFS
u1xCn\
1¡£Ò»¸öÈËÌýµ½ÌáÎÊ£¬ºó»Ø´ðÎÊÌ⣬Çëд³öËù¾¹ýµÄÉñ¾Í¨Â·£¨°´Ë³Ðò£© r1yz ?Y_P
2¡£ÑÓËåºó¶¯Âö¹£ÈûȱѪ¿ÉÄÜÊÜËðµÄÉñ¾½á¹¹¼°ÆäÁÙ´²±íÏÖ¡£ eYMp@Cx
3¡£´ÓÉñ¾·¢Óý½Ç¶È·ÖÎö£¬ÄÔ¸ÉÉñ¾ºËÍŵķֲ¼¹æÂÉ¡£ ^+^#KC8]W
¼ò´ðÌ⣺1¡£Í»´¥ 2¡£×¶ÌåÍâϵ ¡¡¡¡¡¡ x4Mq{MrWp
z;JyHC)
µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ Cb5;l~}L
ѧ¿Æ×¨Òµ£º´«È¾²¡Ñ§ ~tWIVj{
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ 3,=97Si=
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ) gbns'Z<
1. ICAM-1 1%68Pnqk
2. interleukin 12(IL-12) $8vZi
B!"
3. tumor infiltrating lymphocyte Gjfb<
4. TCR/CD3 complex S<H2e{~
5. hematopoietin receptor family +sq'\Tbp
6. individual idiotype(IdI) y_boJ
7. integrin `>-fU<Q1
8. colony-stimulatory factor (CSF) jR[VPm=
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© IcRA[
g
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? Wu3or"lcw*
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ [qbZp1s|(
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ#t
N9#w[K{
4. ¼òÊö¿¹ÔÌá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ x7\b-EC
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) KUJCkwQ
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔÀí¡£ 'EzKu~*
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? }C-K0ba7
x*>@knP<-
J5dwd,FQ
9o%k [n
HiAj3
DO*rVs3'p[
µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ O2x bHn4
uoJ@Jt'j
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ 6g*?(Y][
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ "&Q sv-9t
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© p>#sR4d>
1. CD4 X LHi
2. T cell receptor(TCR) |D*a"*1+A
3. immunoglobulin superfamily (IgSF) >EE}P|=-
4. selectin /{6&99SJcc
5. anti-idiotypic antibody (¦ÁId) z
}3 `9
6. major histocompatibility complex(MHC) :m]KVcF.
7. immunotolerance ?)NgODU
8. biological reponse modifier(BRM) {Jbouj?V!
9. immune reponse gene (Ir gene) t,NE`LC
10. reshaped antibody (or reconstituted antibody) W3+;1S$k
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© g)!d03Qoy
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ f;D(X/"f]
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? HIGTo\]Z
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ v[~~q
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? mX2X.ww(4
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) _xsHU`(J#
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ V~#8lu7;
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? KzZfpdI92
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? `\beQ(g
5Vc~yM
z
¡¡¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ ZAJ~Tbm[f
\J(kevX
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? /Qu<>#[?
U(+%iD60i
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? QVF561Yz
v65]$%F?
¡¡ XL/V>`E@
xsIfR3Ze9
ug_c}Nv=Y
nt%fJ k
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ .unlr_eA
^V~^[Yp
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ lDL(,ZZS`
!'C8sNs
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ $0cE iq?Hf
|hS^eK_
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© }tW1\
@
=
hWiHKR]
1. CD8 aA
-j
=)#<u9
qqL
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) e#vGrLs.
peew<SX
3. immunoglobulin fold(Ig fold) l*Q OM
ewdcAF5
4. cadherin (Ca-dependent cell adhesion moleculers)
,
{}S<^?]
P_P~c~o
5. idiotype-anti-idiotypic antibody immune network theory jgqeDl\=+
~<}?pDA}~
6. HLA class II antigen 9&HaEAme
L*P*^I^1
7. complementarity-determining region (CDR) 1wE`kbC<
A9WOu*G1O
8. perforin(or pore-forming protein ,PFP) @.=2*e.z|b
S/yBr
`
9. high affinity IL-2 receptor ?IDkDv!na~
-aDBdZ;y
10. artificial active immunization ;[7#h8
fG<[zt\e
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© CHdYY7\{
QbYNL9%
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠAY]rQ:I
/AIFgsaY
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 ^fU,9
0Rn`63#
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ ']sIU;h3
#b1/2=PA
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£
>BjZ{7?Ok
bR=TGL&
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£)
j[w5#]&%
K14{c1
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ QjsN7h&%
b~+\\,q}
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? U6M&7l8
mW."lzIl
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ wHErF
#xo
=YR+`[bfI
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ n{E+r
Byns6k
¡¡ Lw{'mtm
vFGVz
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ GV
SVNT}I
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ j,g.Eo
LYS[qLpf
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ _MGhG{p7t
oz?6$oE(bt
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 5?MKx!%
+|Qe/8Q
1. immunoglobulin gene rearrangement tP/R9Ezp
9 Dx9alJR
2. the common chain of cytokine receptor (or a cytokine receptor f@J-6uQ7w
,:/3'L
subunit shared by some cytokine receptors) 3Y=?~!,Jk
n5 jzVv
3. flow cytometry(FCM) 3.I:`>;EO
6Vc&g
4. carrier effect 3+ r8yiY
XDq*nA8#5B
5. positive selection of T lymphocytes in thymus eMDraJv@
S%m$LM]NCg
6. mouse TH1(Th1) and TH2(Th2) subsets }KwL_\>&f
'#0'_9}
7. perforin (pore-forming protein ,PFP) j]5bs*G
)]5}d$83
8. ADCC(antibody-dependent cell-mediated cytotoxicity) 4>W ov
S&YC"
9. SH-2(src-homology region 2) V0x;*)\PYm
2bk~6Osp
10. Ab2¦Â (internal image) [<M~6]
11(:#4Y,
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 3@/\j^U
oMV<Yn_<
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? Xn
1V1sr
iFy_D
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? t$lO~~atr
?W(>Yefk
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠRrGFGn{
0qj:v"~
Q
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ _3YuPMaN
sV))Z2sq
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ?2#MU
z"n7du}v
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) +
q/ j
pp#xN/V#a
ÃâÒßѧרҵ£º ,33[/j
0Y81B;/F
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ \Y0o~JD
kIlc$:K^
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? N:]71+
;p!|E3o.
´«È¾²¡Ñ§×¨Òµ£º F?wfh7q
:4f>S)m
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ \CP)$0j-&o
h2SVDKj
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ 78}QaE
avmuI^LLs
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ ,F,\bp }
UbD1h_b
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? \pXs&}%1,F
#E?T E
aL9yNj}2
Nq`@ >Ml
(h}5*u%h
8
z) K
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ o=t@83Fh5
`OL@@`'^{S
ÃâÒßѧÊÔÌâ u?(@hUV.
raWs6b4Q
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© #y<KO`Es
T<hS
1. Fas(CD95)/FasL yqEX0|V%
q#{.8H-X'
2. common chain of cytokine receptor VH.mH<
{XHAQ9'
3 . TCR/CD3 complex V`/E$a1&
y$
L@!r/s
4. negaive selection of thymocytes S}O>@%
Fgx{ s%&-
5. artificial active immune :y/1Jf'2f
#ujry.m
6. anti-idiotypic (E{>L).~
)\S3Q
7. IgSF QKW\z aG
N\,[(LbA&
8. Integrin PykVXZ7j;
\#
p@ef
9. chemokine 7U9*-9
yQT
cO^E
10. B7/CD28 &d%\&fCm(
VjI=5)+~
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© Z<wJ!|f
M_I.Y1|
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ 6`PQP;
(#&-ld
6
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ D6$*#D3U
/5!0wxN
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ R)@2={fd}
xU1_L*tu '
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ t)4><22of
DruiiA
JdM0f!3
7C&J88|\
CN{xh=2qY[
"1l$]=C*
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ h-f`as"d
t] CA!i`
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© kl~)<,/@
Mp?Gi7o=
1. B7/CD28 e7Sp?>-d
\{a!Z&df
2. Th1 subset +SB>>
Q}: $F{
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© 9+iz+
`53S[8
4. antibody affinity maturation +8|9&v`
oj(st{,
5. AP-1 2<T/N
9Tg
k=
6. single chain variable fragment£¨ScFv£© GBl[s,g[|
Zsn@O2
7. NK cell receptor a&Z,~Vp
fm^J-
8. Zinkernagel-Doherty phenomenon 9s
N#l
S,s#D9NU
9. Ig fold y9N6!M|'y
^;9<7h[l
10. CD40/CD40L =)s~t|@v
o%,?v
9
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© drxCjuz"
?t/G@
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ UcKVLzKs
O#k eoC4
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ =A*a9c2
Lq62
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ Dkx}}E:<
sYfm]Faz
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ L]%!YP\<T
~"_!O+Pj
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ V!(7=ku!`
RU=\eD
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ !x:{"
wwRPfr[
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ cs7^#/3<
&Z3%UOY
Bd 0oA
)i
6"o=`Sq
*p=enflU
}]#z0'Aqsu
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ KxD/{0F
pY[b[ezb
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© |h%HUa
u
4JU 2x
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© *>"NUHq
*];
QPi~
1.Co-stimulators (or co-stimulating molecules) {* :^K\-
ul~6zBKO
2.NK-kB Rnoz[1y?0
0e+#{k
3.Immunoglobulin superfamily
';Q8x?BS
P
4t@BwU$
4.antigen-presenting cell (APC) UGd\`*
Cj
N*hV/"joZ
5.death domain Ww60-d}}Q
DQ3L=
6.CCR and CXCR S9r?= K
I*^t!+q$
7.Lectin (or mitogen) ?}v/)hjp=?
{d*OJ/4
8.Clusters of differentiation, CD) 4_iA<}>|
G
S=E6
9.B7 family 49M1^nMvoo
I<CrEL<5}~
10.Cytotoxic T lymphocyte, CTL) f,E7eL@
\eNB L[
11.IL-15 and IL-15 receptor (IL-15R) zs Q|L
wQ
2[Lv_<i|
12.MHC restriction "r_wgl%
3.?be.cq
13.Affinity-chromatography a{r"$>0
3k9n*jY0
14.Cyctosprin A, CsA Uzzm2OS`
<^Vj1s
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) O#ZZ PJ"
xmcZN3 ){+
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© f\dfKNm6
^_|kEvk0
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ]/1\.<uJId
a24 AmoWx
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ i,*m(C@F}
s2G9}i{
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ B F<u3p??
RSym9t90t
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
SW#/;|m
zZCRej
ÃâÒßѧרҵ£º 5\b GCf
Mz6(M,hkq
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ }l7+W4~
H"l4b4)N\
Ïû»¯ÄÚ¿Æ£º l(sVnhL6h
v5S9h[gT
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 0W*{ 1W
P{n#
^4
ѪҺ²¡Ñ§×¨Òµ£º E@ U]k$M
Yn}Gj'
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ ed
p
I?
hHE~/U
|^1U<'oM#
2P"9m
tf~B,?
8~o']B;lJ
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ,D+ydr
%)JEYH7Z
(רҵ»ù´¡: ÃâÒßѧ) 13!@LbC
luf5-XT
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) XX~vg>3_
|q77
1. ADCC(antibody dependent cell-mediated cytotoxicity) k
<oB9J
^Q s}2%
2. »·æß¾úËØ(cyclosporin) K.)!qkW-%S
^ F]hW
3. KIR(killer cell inhibitory receptor) r<+C,h;aww
2!/Kt
O)i^
4. HLDA(human leucocyte differentiation antigen) lhN@,q
K|7"YNohfG
5. Interleukin 18(IL-18) ^Pn|Q'{/p
6. ÕûºÏËØ(integrin) x4'@U<
7. Fas/FasL b&
z#ZY
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) Uk?G1]$mL
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) XQ]K,# i
10. Th1/Th2 OM\J4"YV$
11. »ùÒòÒßÃç(DNAÒßÃç) ~R!1{8HP
12. chemokines and chemokine receptor l76=6Vtb
13. ÃâÒßÄÍÊÜ #aP#r4$
14. ¹²´Ì¼¤·Ö×Ó _ .v G)
15. ËÀÍö½á¹¹Óò(death domain) o^"+X7)
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) g&Vhu8kNIA
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? .G8`Ut Z
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠm!V,W*RNr
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î &`D$w?beg
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ !vSI"$xd
(3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå Ds`e-X)O;\
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ MpCPY"WLL
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ D#g-mqar:
5
D|#l*V
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) Q
dj(D\.
ÎÊ´ðÌâ(ÿÌâ25·Ö) 0j$\k|xFXZ
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ clE9I<1v
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ (Z),gxt
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ ?J
rUZXY
4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£ K.Xy:l*z
W{6QvQD8
µÚËľüÒ½´óѧһ¾Å¾Å°ËÄ격ʿѧλÑо¿ÉúÈëѧÊÔÌâ q)q3p
VE\L&d2S
·Ö×ÓÉúѧ(2)¡ª¡ª×¨Òµ»ù´¡ m06'T2 I
4)8k?iC*
-------------------------------------------------------------------------------- fv;Q*; oC&
jD
S?p)&
¡¡ U2VEFm6
!sT>]e
Ò»¡¢½âÊÍÏÂÁÐÃû´Ê£¨Ã¿Ìâ5·Ö£¬¹²40·Ö£© )UR$VL
1. µ°°×¼¤Ã¸(protein kinase) A*h8 o9M
2. ÔöÇ¿×Ó(enhancer) e@'x7Zzh
3. SH2½á¹¹Óò(SH2 domain) ?JuJu1
4. ¾ÛºÏøÁ´·´Ó¦(PCR) nW=6nCyvo
5. »ùÒòÖÎÁÆ(gene therapy) gwj?.7N*k
6. ±äÐÔµ°°×ÖÊ(denatrued protein) 1
iH@vd
7. ÐźÅëÄ(signal peptide) Tuvs}
8. cDNAÎÄ¿â uKx:7"KD
¶þ¡¢ÎÊ´ðÌâ(Ñ¡´ðËĵÀÌâ,¹²¼Æ60·Ö) }&v}S6T
1. ʲôÊǵ°°×ÖʵÄÒ»¼¶¡¢¶þ¼¶¡¢Èý¼¶¡¢Ëļ¶½á¹¹£¿ËüÃÇÒÀ¿¿Ê²Ã´ÑùµÄÁ´ºÍÁ¦½¨Á¢ÆðÕâЩ½á¹¹£¿ËüÃÇÖ®¼äµÄ¹ØÏµÊÇʲô£¿(15·Ö) *bK=<{d1P
2. ¼òÊöÖØ×éDNA¼¼ÊõµÄ¶¨Òå¡¢ÔÀíºÍÖ÷Òª¹ý³Ì£¬½áºÏÄãµÄרҵ¾Ù³öÒ»¸öÓ¦Óøü¼ÊõµÄʵÀý²¢ËµÃ÷ÆäÒâÒå¡£(15·Ö) *l7 `C)
3. ¼òÊö°©»ùÒòÓëÒÖ°©»ùÒòµÄ¶¨Òå,¸÷¾ÙÒ»Àý˵Ã÷ÆäÔÚÖ×Áö·¢ÉúÖеÄ×÷Óá£(15·Ö) Xu{y5N
4. ÒÔÈéÌDzÙ×Ý×Ó(»ò³ÆÎªÈéÌDzÙ×ÝÔª)ºÍÉ«°±Ëá²Ù×Ý×ÓΪÀý¼òÊöÔºËϸ°û»ùÒò±í´ïµ÷¿ØÔÀí¡£(15·Ö) 5gz ^3R|`f
5. ¼òÊöÕæºËϸ°û»ùÒò±í´ïµ÷¿ØµÄ»ù±¾»·½Ú¡¢Ö÷ÒªµÄµ÷¿Ø·Ö×Ӻ͵÷¿Ø·½Ê½¡£(15·Ö) H I9/
×¢Ò⣺ÇëÑ¡´ðËĵÀÌ⣬¶à´ðÕß¿ÛÈ¥µÃ·Ö×î¶àµÄ´ðÌ⣡£¡